Showing results (61-70 of 100) with videos related to
Sort By:
Pageof 10
International Journal of Oncology|May 4, 2012
Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC studyFrançoise Descotes, Pascal Jézéquel, Frédérique Spyratos, et al.European Journal of Cancer (Oxford, England : 1990)|March 11, 2017
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 statusSylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2026
Aromatase Inhibitor-Induced Arthralgia Among Patients With Early Breast Cancer: Prevalence, Treatment Nonadherence, and Management in a Prospective Longitudinal CohortPietro Lapidari, Maryam B Lustberg, Julie Havas, et al.Breast Cancer Research : BCR|February 19, 2025
Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal studyMylène Duivon, François Christy, Emilie Thomas, et al.NPJ Breast Cancer|February 13, 2025
Clinico-pathological factors predicting pathological response in early triple-negative breast cancerClara Helal, Lounes Djerroudi, Toulsie Ramtohul, et al.Breast (Edinburgh, Scotland)|March 12, 2021
Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancerPietro Lapidari, Arnauld Gbenou, Julie Havas, et al.Psycho-Oncology|October 14, 2020
Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohortIsabelle Hardy-Leger, Cécile Charles, Marie Lange, et al.Journal of the National Cancer Institute|September 3, 2025
Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohortDaniele Presti, Antonio Di Meglio, Julie Havas, et al.The Lancet. Oncology|April 1, 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.Oncotarget|February 28, 2016
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 studyEmeline Tabouret, François Bertucci, Jean-Yves Pierga, et al.Pageof 10